Tiffany, Kors to Re...
Health Care: Drugs
Teva Pharmaceutical Industries Ltd (TEVA: NYSE)
$39.34 -0.15 | -0.38%
05/24/13 - 04:02 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 2.88B | 1.10B | 1.25B | 2.00B |
| Receivables | 5.57B | 6.21B | 5.48B | 5.02B |
| Inventories | 5.50B | 5.01B | 3.87B | 3.33B |
| Other Current Assets | 1.26B | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 16.36B | 14.45B | 12.04B | 12.14B |
| Property, Plant & Equipment, Gross | 9.14B | 8.38B | 6.62B | 5.69B |
| Accumulated Depreciation & Depletion | 2.82B | 2.43B | 2.26B | 1.92B |
| Property, Plant & Equipment, Net | 6.32B | 5.95B | 4.36B | 3.77B |
| Intangibles | 7.74B | 10.32B | 5.75B | 4.05B |
| Other Non-Current Assets | 1.34B | 991.00M | 632.00M | 534.00M |
| Total Non-Current Assets | 34.25B | 35.69B | 26.11B | 21.67B |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 50.61B | 50.14B | 38.15B | 33.81B |
| Accounts Payable | 3.38B | 3.74B | 2.52B | 2.68B |
| Short Term Debt | 3.01B | 3.75B | 1.43B | 1.30B |
| Other Current Liabilities | 6.51B | 5.82B | 4.40B | 3.62B |
| Total Current Liabilities | 12.89B | 13.85B | 9.69B | 7.60B |
| Long Term Debt | 11.71B | 10.24B | 4.11B | 4.31B |
| Deferred Income Taxes | 1.85B | 2.61B | 1.35B | 1.74B |
| Other Non-Current Liabilities | 1.29B | 1.11B | 998.00M | 897.00M |
| Minority Interest | -53.00M | 9.00M | 8.00M | 4.00M |
| Total Non-Current Liabilities | 14.95B | 14.10B | 6.51B | 6.99B |
| Total Liabilities | 27.84B | 27.95B | 16.20B | 14.59B |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 22.77B | 22.20B | 21.95B | 19.22B |
| Common Par | 50.00M | 50.00M | 49.00M | 49.00M |
| Additional Paid In Capital | 13.47B | 13.37B | 13.25B | 12.88B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | 12.35B | 11.28B | 9.32B | 6.66B |
| Treasury Stock | -3.08B | -1.92B | -1.02B | -924.00M |
| Other Equity Adjustments | -17.00M | -589.00M | 350.00M | 555.00M |
| Total Capitalization | 34.48B | 32.43B | 26.06B | 23.53B |
| Total Equity | 22.77B | 22.20B | 21.95B | 19.22B |
| Total Liabilities & Stock Equity | 50.61B | 50.14B | 38.15B | 33.81B |
| Total Common Shares Outstanding | 856.62M | 882.99M | 897.50M | 885.40M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 87.00M | 118.00M | 40.00M | 38.00M |
| Basic Weighted Shares Outstanding | 872.00M | 890.00M | 896.00M | 872.00M |
| Diluted Weighted Shares Outstanding | 873.00M | 893.00M | 921.00M | 896.00M |
| Number of Employees | 45948 | 45754 | 39660 | 35089 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with TEVA
- Portfolio NameUser Type
- UserDonnie Portfolio 2 High Grade
- UserMain
- UserLong Term Stock Picks
- UserTRIG
- Userfun and games
- Userabangser Portfolio 1
- ContributorHighest-Yielding Drug Stocks
- Contributor8 Pharma Stocks to Watch
- Userdividend
- UserIncome stocks
Latest TEVA Headlines from TheStreet
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 04.18.13 | 10:04 am
- 5 Stocks Pulling The Drugs Industry Downward 04.12.13 | 01:04 pm
- Cramer's Top Stock Picks: BMY TEVA ROST BBBY 04.12.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Bubble? What Bubble? 04.11.13 | 08:04 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 04.08.13 | 10:04 am
- 3 Stocks Improving Performance Of The Health Care Sector 04.03.13 | 01:04 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 03.28.13 | 10:03 am
- 4 Stocks Dragging The Drugs Industry Downward 03.27.13 | 01:03 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 03.18.13 | 10:03 am
- Analysts' Actions: BTU HLS HPQ ODP TEVA 03.18.13 | 08:03 am
Press Releases for TEVA
- Apolo Anton Ohno And Teva Respiratory Announce Finalists In National EIB All Starsâ¿¢ Contest - PR Newswire 04.16.13 | 08:04 am
- OncoGenex Announces Plans For The Initiation Of The Spruceâ¿¢ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer - PR Newswire 04.11.13 | 08:04 am
- Early Versus Delayed Treatment With Laquinimod Demonstrated Significant Reduction In Risk Of Disability Progression – Results Of Three-Year ALLEGRO Study In Relapsing-Remitting Multiple Sclerosis - Business Wire 03.21.13 | 08:03 am
- New Data Show Azilect® (rasagiline Tablets) Provided Clinical Benefit In Patients With Early Parkinson’s When Added To Sub-Optimally Controlled Patients On Dopamine Agonist Therapy - Business Wire 03.20.13 | 07:03 am
- Teva To Present New Research On CNS Product Portfolio And Pipeline At 2013 American Academy Of Neurology Annual Meeting - Business Wire 03.14.13 | 09:03 am
- Clay Walker, Country Music Star And Relapsing-Remitting Multiple Sclerosis Patient Urges Others To "Stick With It" - PR Newswire 03.13.13 | 08:03 am
- Teva Files 2012 Annual Report On Form 20-F - Business Wire 03.08.13 | 04:03 pm
- First Patient Enrolled In Third Phase III Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis - Business Wire 03.06.13 | 08:03 am
- Phase III Study Of Teva’s Milprosa™ (Progesterone) Vaginal Ring Published In Fertility And Sterility - Business Wire 03.04.13 | 08:03 am
- Teva Calls 5.550% Senior Notes Due 2016 For Redemption - Business Wire 03.01.13 | 09:03 am
Partner Headlines for TEVA
- Teva Pharmaceutical Industries Limited Earnings Preview: Get Ahead of the Analysts - Wall St. Cheat Sheet 05.02.13 | 10:05 am
- Teva Pharmaceutical Industries Limited Earnings: Here’s Why the Stock is Up Now - Wall St. Cheat Sheet 05.02.13 | 09:05 am
- Analysts: SanDisk Will Beat Estimates and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- FDA Approves NDA for Teva's Quartette Tablets to Prevent Pregnancy - Benzinga 03.29.13 | 11:03 am
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- Biogen MS Drug Approved; No 'Black Box' Label - Investor's Business Daily 03.27.13 | 06:03 pm
- Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind - Seeking Alpha 03.25.13 | 09:03 am
- Valeant Earnings, Sales Top Estimates; Street Shrugs - Investor's Business Daily 02.28.13 | 05:02 pm
- 3 Industries Set To Profit From An Aging Population - Seeking Alpha 01.31.13 | 09:01 am
